FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--ImmunSYS, Inc., a clinical stage biotechnology company focused on the development of innovative cancer immunotherapy products, announced today that Douglas G. Watson joined its Board of Directors as Lead Independent Director, effective December 28, 2018.
“Doug has a stellar track record in senior executive leadership and board roles at both publicly-traded and private companies and brings a wealth of pharmaceutical and biotech industry expertise to the ImmunSYS Board of Directors,” said Eamonn Hobbs, Chairman and CEO of ImmunSYS. “His appointment as Lead Independent Director comes as we enter our next phase of growth and his insights will be critical to our success moving forward.”
“ImmunSYS has developed a unique, innovative, outpatient immunotherapy that has demonstrated very impressive early clinical results in the treatment of late stage metastatic prostate cancer,” said Mr. Watson. “By applying IP-protected technology and following a rigorous development program, I believe that the ImmunSYS technology can generate clinical results that will dramatically improve late stage metastatic prostate cancer patients’ quality and quantity of life and reduce healthcare costs. I’m delighted to be joining the ImmunSYS Board as the company advances the development of this potential breakthrough in late stage metastatic prostate cancer therapy.”
Mr. Watson is the founder of Pittencrieff Glen Associates, which he established in June of 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson’s career spanned 33 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the US. He was President of Ciba Pharmaceuticals’ US Division from 1986 until 1996, when he was appointed President and CEO of Ciba-Geigy Corporation. During this ten-year period, Mr. Watson was an active member of the Pharmaceutical Research and Manufacturers Association (PhRMA) Board in Washington, DC. In 1997, when Ciba-Geigy and Sandoz merged, Mr. Watson became President and CEO of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson elected to take early retirement from Novartis in May, 1999.
Mr. Watson currently serves as a member of the Board of BZL Inc., and a member of the Advisory Board of Cancer Expert Now Inc. Prior Board memberships include OraSure, Novartis, Engelhard, Summit Bank, Wright Medical Group Inc., BioMimetic Therapeutics Inc., Delcath Systems Inc., Dendreon, Javelin Pharmaceuticals Inc., Genta Inc., and Bionor Immuno AS.
ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other adenocarcinomas. The company’s platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energy delivery device system, a proprietary branded formulation of immunotherapeutic drugs, and a proprietary procedure developed by the focal prostate cancer pioneer and inventor of the male lumpectomy, Gary Onik, M.D.
This new immunotherapy therapy is designed to empower the immune system to recognize and selectively attack cancer cells. The company is initially developing this new cancer therapy for the treatment of late-stage metastatic prostate cancer, with a pipeline of additional development programs for other cancers. For more information about the company and its programs, visit http://www.immunsys.com/.
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this new release are made only as of the date hereof, and the company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.